Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Zambelli

Showing results (111-120 of 162) with videos related to

Pageof 17
Sort By:
Breast (Edinburgh, Scotland)|November 15, 2022
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical OncologyFederica Miglietta, Michela Cinquini, Maria Vittoria Dieci, et al.
Breast Cancer Research and Treatment|January 24, 2024
Real-world use of multigene signatures in early breast cancer: differences to clinical trialsLuca Licata, Rita De Sanctis, Andrea Vingiani, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 2, 2024
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patientsElena Giordani, Matteo Allegretti, Alberto Sinibaldi, et al.
Nature Cell Biology|June 28, 2016
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancerDawid Walerych, Kamil Lisek, Roberta Sommaggio, et al.
EMBO Molecular Medicine|April 19, 2015
Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expressionFloriana Centritto, Gabriela Paroni, Marco Bolis, et al.
Plos One|May 26, 2016
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC StudyStefania Gori, Alessandro Inno, Valentina Rossi, et al.
Targeted Oncology|September 24, 2022
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 StudyMichelino De Laurentiis, Roberta Caputo, Manuelita Mazza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2023
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast CancerFederica Miglietta, Moira Ragazzi, Bethania Fernandes, et al.
Journal of the National Cancer Institute|March 4, 2025
Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugatesLaura Pala, Federico Merlo, Isabella Sala, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2023
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trialLuca Malorni, Giampaolo Bianchini, Roberta Caputo, et al.
Pageof 17

Showing results (111-120 of 162) with videos related to

Sort By:
Pageof 17
Breast (Edinburgh, Scotland)|November 15, 2022
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical OncologyFederica Miglietta, Michela Cinquini, Maria Vittoria Dieci, et al.
Breast Cancer Research and Treatment|January 24, 2024
Real-world use of multigene signatures in early breast cancer: differences to clinical trialsLuca Licata, Rita De Sanctis, Andrea Vingiani, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 2, 2024
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patientsElena Giordani, Matteo Allegretti, Alberto Sinibaldi, et al.
Nature Cell Biology|June 28, 2016
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancerDawid Walerych, Kamil Lisek, Roberta Sommaggio, et al.
EMBO Molecular Medicine|April 19, 2015
Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expressionFloriana Centritto, Gabriela Paroni, Marco Bolis, et al.
Plos One|May 26, 2016
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC StudyStefania Gori, Alessandro Inno, Valentina Rossi, et al.
Targeted Oncology|September 24, 2022
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 StudyMichelino De Laurentiis, Roberta Caputo, Manuelita Mazza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2023
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast CancerFederica Miglietta, Moira Ragazzi, Bethania Fernandes, et al.
Journal of the National Cancer Institute|March 4, 2025
Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugatesLaura Pala, Federico Merlo, Isabella Sala, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2023
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trialLuca Malorni, Giampaolo Bianchini, Roberta Caputo, et al.
Pageof 17